Business Description
Immuno-Biological Laboratories Co Ltd
1091-1 Naka Aza-Higashida, Gunma, Fujioka, JPN, 375-0005
Compare
Compare
Traded in other countries / regions
4570.Japan
Description
Immuno-Biological Laboratories Co., Ltd. focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.17 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.94 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 4.04 | |||||
| Beneish M-Score | -3.27 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -9.1 | |||||
| 3-Year EBITDA Growth Rate | -11.6 | |||||
| 3-Year EPS without NRI Growth Rate | -11.9 | |||||
| 3-Year FCF Growth Rate | 29.8 | |||||
| 3-Year Book Growth Rate | -15.8 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.65 | |||||
| 9-Day RSI | 46.77 | |||||
| 14-Day RSI | 50.7 | |||||
| 6-1 Month Momentum % | 9.45 | |||||
| 12-1 Month Momentum % | -27.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.95 | |||||
| Quick Ratio | 3.52 | |||||
| Cash Ratio | 2.23 | |||||
| Days Inventory | 435.99 | |||||
| Days Sales Outstanding | 94.6 | |||||
| Days Payable | 8.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.17 | |||||
| Operating Margin % | -18.87 | |||||
| Net Margin % | -39.96 | |||||
| ROE % | -17.65 | |||||
| ROA % | -14.85 | |||||
| ROIC % | -10.58 | |||||
| ROC (Joel Greenblatt) % | -46.91 | |||||
| ROCE % | -16.05 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.69 | |||||
| PB Ratio | 2.7 | |||||
| Price-to-Tangible-Book | 2.7 | |||||
| EV-to-EBIT | -13.68 | |||||
| EV-to-EBITDA | -13.68 | |||||
| EV-to-Revenue | 5.27 | |||||
| EV-to-FCF | -36.63 | |||||
| Price-to-Median-PS-Value | 0.68 | |||||
| Price-to-Net-Current-Asset-Value | 4.65 | |||||
| Price-to-Net-Cash | 21.52 | |||||
| Earnings Yield (Greenblatt) % | -7.31 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 647.576 | ||
| EPS (TTM) (円) | -27.786 | ||
| Beta | 0.48 | ||
| Volatility % | 59.67 | ||
| 14-Day RSI | 50.7 | ||
| 14-Day ATR (円) | 24.743783 | ||
| 20-Day SMA (円) | 400.6 | ||
| 12-1 Month Momentum % | -27.77 | ||
| 52-Week Range (円) | 285 - 530 | ||
| Shares Outstanding (Mil) | 9.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immuno-Biological Laboratories Co Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||